C4X Discovery Holdings PLC - ESG Rating & Company Profile powered by AI
This Disclosure score includes seventeen UN SDGs including: 'Affordable & Clean Energy', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. Scroll down to the bottom of this webpage for potential risks for C4X Discovery Holdings PLC based on sector, location and marketcap. Alternative corporations in the scoring industry group for C4X Discovery Holdings PLC are shown below.
C4X Discovery Holdings PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.5; made up of an environmental score of 8.0, social score of 6.4 and governance score of 8.0.
7.5
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
149 | Torrent Pharmaceuticals Ltd | 7.6 | High |
149 | Virbac SA | 7.6 | High |
160 | C4X Discovery Holdings PLC | 7.5 | High |
160 | Ascentage Pharma Group International | 7.5 | High |
160 | Kindred Biosciences Inc | 7.5 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does C4X Discovery Holdings PLC have an accelerator or VC vehicle to help deliver innovation?
Does C4X Discovery Holdings PLC disclose current and historical energy intensity?
Does C4X Discovery Holdings PLC report the average age of the workforce?
Does C4X Discovery Holdings PLC reference operational or capital allocation in relation to climate change?
Does C4X Discovery Holdings PLC disclose its ethnicity pay gap?
Does C4X Discovery Holdings PLC disclose cybersecurity risks?
Does C4X Discovery Holdings PLC offer flexible work?
Does C4X Discovery Holdings PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does C4X Discovery Holdings PLC disclose the number of employees in R&D functions?
Does C4X Discovery Holdings PLC conduct supply chain audits?
Does C4X Discovery Holdings PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does C4X Discovery Holdings PLC conduct 360 degree staff reviews?
Does C4X Discovery Holdings PLC disclose the individual responsible for D&I?
Does C4X Discovery Holdings PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does C4X Discovery Holdings PLC disclose current and / or historical scope 2 emissions?
Does C4X Discovery Holdings PLC disclose water use targets?
Does C4X Discovery Holdings PLC have careers partnerships with academic institutions?
Did C4X Discovery Holdings PLC have a product recall in the last two years?
Does C4X Discovery Holdings PLC disclose incidents of discrimination?
Does C4X Discovery Holdings PLC allow for Work Councils/Collective Agreements to be formed?
Has C4X Discovery Holdings PLC issued a profit warning in the past 24 months?
Does C4X Discovery Holdings PLC disclose parental leave metrics?
Does C4X Discovery Holdings PLC disclose climate scenario or pathway analysis?
Does C4X Discovery Holdings PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does C4X Discovery Holdings PLC disclose the pay ratio of women to men?
Does C4X Discovery Holdings PLC support suppliers with sustainability related research and development?
Does C4X Discovery Holdings PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does C4X Discovery Holdings PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is C4X Discovery Holdings PLC involved in embryonic stem cell research?
Does C4X Discovery Holdings PLC disclose GHG and Air Emissions intensity?
Does C4X Discovery Holdings PLC disclose its waste policy?
Does C4X Discovery Holdings PLC report according to TCFD requirements?
Does C4X Discovery Holdings PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does C4X Discovery Holdings PLC disclose energy use targets?
Does C4X Discovery Holdings PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does C4X Discovery Holdings PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for C4X Discovery Holdings PLC
These potential risks are based on the size, segment and geographies of the company.
C4X Discovery Holdings plc operates as a drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality. The company's product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, GEN-COVID, LifeArc, Indivior PLC, Phoremost, AstraZeneca UK Limited, and Evotec SE. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was incorporated in 2007 and is based in Manchester, the United Kingdom.